New hope for tough blood cancers: experimental drug JNJ-90189892 enters human testing
NCT ID NCT06651229
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial is testing an experimental drug called JNJ-90189892 in about 155 people with acute myeloid leukemia (AML) or myelodysplastic neoplasms (MDS) that have come back or not responded to treatment. The study has several parts: first, finding a safe dose of JNJ-90189892 alone, then testing it in combination with two other drugs (azacitidine and venetoclax) in both relapsed/refractory and newly diagnosed AML. The main goals are to check safety and find the right dose for future studies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
JNJ-90189892 (an experimental drug) given alone or with azacitidine and venetoclax
What this could lead to
If successful, this could point toward a new treatment option for people with hard-to-treat AML or MDS.
What could go wrong
This is an early Phase 1 trial, so the main goal is safety, not proof of effectiveness. Many experimental drugs fail at this stage, and side effects may be serious.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA, MYELOID, ACUTE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHRU de Strasbourg - Hopital de Hautepierre
RECRUITINGStrasbourg, 67200, France
-
Clinica Univ. de Navarra
RECRUITINGPamplona, 31008, Spain
-
Concord Hospital
RECRUITINGConcord, 2139, Australia
-
Hosp Univ Fund Jimenez Diaz
RECRUITINGMadrid, 28040, Spain
-
Hospital Universitario Virgen Rocio
RECRUITINGSeville, 41013, Spain
-
Institut Claudius Regaud
RECRUITINGToulouse, 31100, France
-
Institut Paoli-Calmettes
RECRUITINGMarseille, 13273, France
-
Peter MacCallum Cancer Centre
RECRUITINGMelbourne, 3000, Australia
-
Sir Charles Gairdner Hospital
RECRUITINGNedlands, 6009, Australia